Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-Trop2 U-CAR-NK Therapy for Relapsed/Refractory NSCLC
NCT06454890Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2024
- Primary completion
- Jul 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
A Phase 2 trial of anti-Trop2 U-CAR-NK cells in non-small cell lung cancer (NSCLC), sponsored by Henan Cancer Hospital. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
anti-Trop2 U-CAR-NK cells
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06454890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06454890.